Fig. 2
Effect of amisulpride augmentation therapy on Positive and Negative Syndrome Scale (PANSS) scores. At week 6 and 12, the amisulpride group displayed lower PANSS total score, positive symptom subscore, and general psychopathology subscore compared with the placebo group (week 6:F = 11.18, P = 0.001, PBonferroni = 0.004, Cohen’s d = 0.88; F = 16.63, P < 0.0001, PBonferroni < 0.0001, Cohen’s d = 0.99; F = 12.56, P = 0.001, PBonferroni = 0.004, Cohen’s d = 0.89. week 12:F = 11.34, P = 0.001, PBonferroni = 0.004, Cohen’s d = 0.45; F = 17.10, P < 0.0001, PBonferroni < 0.0001, Cohen’s d = 0.97; F = 14.00, P < 0.0001, PBonferroni < 0.001, Cohen’s d = 0.92). **P < 0.01, ***P < 0.001; ns non-significant